Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -1.34% and Operating profit at -14.45% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
3
With ROE of 5.95%, it has a attractive valuation with a 0.92 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,299 Million (Mid Cap)
23.00
NA
6.77%
-0.45
5.56%
1.04
Revenue and Profits:
Net Sales:
1,803 Million
(Quarterly Results - Jun 2026)
Net Profit:
208 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.45%
0%
-6.45%
6 Months
-12.45%
0%
-12.45%
1 Year
-19.28%
0%
-19.28%
2 Years
-13.1%
0%
-13.1%
3 Years
-50.34%
0%
-50.34%
4 Years
-43.59%
0%
-43.59%
5 Years
-64.98%
0%
-64.98%
By-health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.34%
EBIT Growth (5y)
-14.45%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.56
Tax Ratio
19.81%
Dividend Payout Ratio
96.38%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
19.75%
ROE (avg)
14.00%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
1.36
EV to EBIT
14.21
EV to EBITDA
11.04
EV to Capital Employed
1.62
EV to Sales
1.69
PEG Ratio
0.26
Dividend Yield
4.90%
ROCE (Latest)
11.44%
ROE (Latest)
5.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
1,802.60
1,740.60
3.56%
Operating Profit (PBDIT) excl Other Income
346.50
420.60
-17.62%
Interest
1.90
3.90
-51.28%
Exceptional Items
18.60
26.00
-28.46%
Consolidate Net Profit
207.50
296.90
-30.11%
Operating Profit Margin (Excl OI)
151.70%
198.90%
-4.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 3.56% vs -11.51% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -30.11% vs 84.18% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,218.40
6,805.50
-8.63%
Operating Profit (PBDIT) excl Other Income
1,178.80
998.80
18.02%
Interest
15.80
13.80
14.49%
Exceptional Items
27.70
28.00
-1.07%
Consolidate Net Profit
816.60
647.90
26.04%
Operating Profit Margin (Excl OI)
142.90%
109.20%
3.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -8.63% vs -26.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 26.04% vs -63.58% in Dec 2024
About By-health Co., Ltd. 
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






